NCT00973128View on ClinicalTrials.gov

Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

October 31, 2006

Study Completion Date

May 31, 2007

Conditions
Cutaneous Leishmaniasis
Interventions
DRUG

GMCSF plus Antimony reduced dose

400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)

DRUG

Meglumine antimoniate

20mg/daily for 20 days

Trial Locations (1)

Unknown

Health Post of Corte de Pedra, Valença

All Listed Sponsors
collaborator

Fundação de Amparo à Pesquisa do Estado da Bahia

OTHER

lead

Hospital Universitário Professor Edgard Santos

OTHER

NCT00973128 - Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis | Biotech Hunter | Biotech Hunter